
OPENS.
DELIVERS.
MAINTAINS.
35%
reduction in post-FESS medical/surgical therapies
46%
reduction in frank polyposis
40%
reduction in need for oral steroids
PROPEL's meta-analysis provides Level 1-A evidence - a first in ENT - demonstrating the benefit of localized steroid release in the post-FESS period[1]
PROPEL™
MOMETASONE FUROATE IMPLANT

1 PROPEL OPENS.

Designed with patient comfort in mind, the Propel™ Steroid-Releasing implant props opens the sinuses after surgery through an innovative spring-like design.

2 PROPEL DELIVERS.

The Propel Steroid-Releasing implant is the first and only product that delivers drug directly to the sinus mucosa, reducing the need for oral steroids.

3 PROPEL MAINTAINS.

Propel is clinically proven to maintain the outcomes your surgery creates — providing confidence that your work will stay as you left it.

PROPEL. CLINICALLY PROVEN.

Safety and efficacy of PROPEL Steroid-Releasing Implant has been studied in three prospective clinical trials conducted in the United States enrolling a total of 205 patients.

PROPEL provides clinically and statistically significant benefits to patients.

- Maintains patency by reducing post-operative adhesions, inflammation, polyposis & middle turbinate lateralization. Reducing these post-op factors is proven to improve long term outcomes and reduce the need for revision surgery [2]
- Decreases need for post-operative medical and surgical therapies, including adhesion lysis and oral steroid therapy.

Studied in a Broad Patient Population:

- > 60% polyps at baseline
- > 30% prior sinus/nasal surgery
- > 12 Mean Lund-Mackay CT stage

Safety Demonstrated:

- Ocular safety: No clinically significant changes from baseline in intraocular pressure or lens opacities
- Systemic safety: No evidence of systemic steroid exposure or adrenal-pituitary axis suppression





PROPEL VS. CONTROL AT 30 DAYS. [3]



Control Implant on right side at day 0



PROPEL Steroid-Releasing Implant on left at day 0



Control side at day 30



PROPEL side at day 30

PRODUCT NAME:

PROPEL™ mometasone furoate implant, 370ug

MANUFACTURER AND CATALOG:

Intersect ENT
#70011

VENDOR CONTACT INFORMATION:

Customer Service
Telephone: 866-531-6004
Fax: 866-736-1251
customerservice@intersectENT.com
www.intersectENT.com

1) Han JK, Marple BF, Smith TL et al. Int Forum Allergy Rhinol. 2012; 2:271-279.
2) Kennedy et al. Laryngoscope. 2001; 110 (Suppl. 94): 29-31
3) Murr AH, Smith TL, Hwang PH et al. Int Forum Allergy Rhinol. 2011; 1 (1):23-32.

intersect ENT

MPM 00001 Rev.B